(Reuters Health) – Adolescents who have harmed themselves or tried to commit suicide may be less likely to do it again when they participate in an intense therapy program focused on both individual and family treatment, a U.S. study suggests.
(Reuters Health) – Teens who spend lots of time surfing the web, playing games and chatting with friends on smartphones and tablets may be more likely to develop ADHD symptoms than youth who don’t, a U.S. study suggests.
(Reuters Health) – The kind of imaging U.S. women receive after treatment for non-metastatic breast cancer can vary widely, a new study finds.
(Reuters Health) – The 46 medicines given approval through 2017 as part of the U.S. Food and Drug Administration’s Breakthrough Therapy program have often been sent to patients without a large double-blind study, direct measurement of benefit, or compa…
A common blood pressure and heart drug manufactured in bulk by a Chinese company and sold worldwide may have contained an impurity linked to cancer since 2012, European regulators said on Tuesday.
Billionaire Bill Gates and Estée Lauder Cos chairman emeritus Leonard Lauder on Tuesday said they will award $30 million over three years to encourage development of new tests for early detection of Alzheimer’s disease.
Johnson & Johnson on Tuesday reported better-than-expected second quarter profit as sales of pharmaceuticals surged 20 percent despite a sharp decline in blockbuster arthritis drug Remicade, and its shares rose more than 4 percent.
UnitedHealth Group Inc, the largest U.S. health insurer, on Tuesday reported second-quarter medical costs slightly higher than Wall Street expectations, sending its shares down 4 percent and weighing on the rest of the sector.
Johnson & Johnson topped analysts’ estimates for quarterly profit and revenue on Tuesday, as strong demand for cancer drugs Zytiga and Darzalex more than made up for declining sales of blockbuster treatment Remicade.
UnitedHealth Group Inc, the largest U.S. health insurer, reported second-quarter medical costs slightly higher than Wall Street expectations on Tuesday, sending its shares down nearly 2 percent before the opening bell.
UnitedHealth Group Inc Chief Financial Officer John Rex said on Tuesday that patient medical costs are running within the company’s expectations and forecast they will stay that way this year.
AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie’s blockbuster drug Humira, in a move that will give it more near-term control over the competition.
Swiss drugmaker Roche’s hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed its new medicine reduced symptoms in people at high risk of complications.
Swiss drugmaker Roche’s hopes of regaining ground in the influenza market have been boosted after a late-stage study showed its investigational drug baloxavir marboxil reduced symptoms in people at high risk of complications.
Roche said on Tuesday its investigational drug baloxavir marboxil reduced symptoms in people at high risk of complications from flu, a boost to the Swiss drugmaker’s efforts to win approval for the single-dose, oral anti-viral medicine.
A federal judge ruled on Monday against birth control organizations that sought to block the Trump administration from shifting a federal family-planning grant program toward prioritizing groups that are faith-based and counsel abstinence.
(Reuters Health) – Young women with unhealthy levels of fats in their blood may have higher odds of having just one child, or no children at all, a recent study suggests.
Silicon Valley e-cigarette start-up Juul Labs is bringing its small flash drive-sized vaping device to the United Kingdom this week, aiming to reproduce its break-neck U.S. growth overseas.
A mass radio campaign in Burkina Faso led to a significant rise in sick children getting medical attention and could prove one of the most cost-effective ways to save young lives in poor countries, researchers said on Tuesday.
The use of gene editing technologies to alter the DNA of human embryos could be morally permissible as long as the science and its impact on society is carefully considered, a British ethics panel said on Tuesday.